Stuart D. Cook

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Gavin Giovannoni, Stuart D. Cook, Kottil Rammohan et al. · New England Journal of Medicine · 2010 · 1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Paul O’Connor, Massimo Filippi, Barry G.W. Arnason et al. · The Lancet Neurology · 2009 · 403 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +8

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook et al. · Multiple Sclerosis Journal · 2017 · 333 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +10

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Gavin Giovannoni, Stuart D. Cook, Kottil Rammohan et al. · The Lancet Neurology · 2011 · 246 citations

Medicine, Neurology, Pharmacotherapy +10

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

Kathryn C. Fitzgerald, Kassandra L. Munger, Karl Köchert et al. · JAMA Neurology · 2015 · 169 citations

Medicine, Neurology, Pharmacotherapy +17